Key Drivers of High Costs in Head and Neck Cancer Care
Advanced disease stage was the strongest predictor of high first-year healthcare costs in Canadian patients with head and neck cancer, a recent analysis found. Patients with stage IV disease had an almost ninefold greater likelihood for high healthcare costs than those with stage I disease. Combination treatments — especially surgery with adjuvant therapy — were also a major driver of high costs.
METHODOLOGY:
Patients with head and neck cancer experience considerable healthcare burdens due to aggressive and complex multimodal treatments, as well as long-term complications requiring rehabilitation and supportive care. Identifying predictors of high first-year costs can guide strategies to optimize resource use and improve patient outcomes.
Researchers conducted a population-based retrospective cohort study using data from 13,795 Ontario, Canada, residents (mean age, 63.2 years; 25% women) who were diagnosed with head and neck cancer between January 2007 and October 2020.
Researchers estimated total 1-year healthcare costs using a patient-level algorithm, with values adjusted to 2020 Canadian dollars (CAD), and identified predictors for high healthcare costs.
Overall, 25% of patients were classified in the high-cost group (≥ 75th percentile; n = 3448), and 75% were classified in the low- or medium-cost group (< 75th percentile; n = 10,347).
Patients in the high-cost vs low- or medium-cost groups were more likely to receive chemoradiotherapy (31.5% vs 19.0%), surgery with radiotherapy (20.0% vs 5.7%), or surgery with chemoradiotherapy (14.4% vs 4.1%), and were less likely to receive surgery alone (11.5% vs 27.4%) or radiotherapy alone (16.7% vs 26.1%).
TAKEAWAY:
Over 1 year, the biggest costs for patients in the high-cost group were inpatient stays (representing 41.0% of costs or CA$40,796 vs CA$5769 in the lower-cost group), outpatient visits (33.5% or $33,321 vs $16,953), physician services (12.5% or $12,436 vs $4959), complex and home care (8.7% or $8677 vs $1272), and drugs, devices, and lab tests (4.2% or $4208 vs $1576).
Stage II (odds ratio [OR], 3.14), stage III (OR, 6.08), and stage IV (OR, 8.94) were associated with progressively greater odds of high healthcare costs than stage I disease.
Combination treatment was associated with substantially greater odds of high costs than no treatment or palliative care (OR, 6.94 for surgery and radiotherapy; OR, 5.86 for surgery with chemoradiotherapy).
Female sex (OR, 1.26) and older age (per each 10-year increase in age at diagnosis; OR, 1.07) were both associated with increased odds of high costs, as were diagnoses during the COVID pandemic (OR, 1.73) compared with prior years.
IN PRACTICE:
'This cohort study found that more advanced disease stage and receiving multiple treatment modalities were the strongest predictors of high-cost care among patients diagnosed with head and neck cancer,' the authors of the study wrote. Potential solutions, they noted, include effective screening programs to promote earlier diagnosis, as well as interventions aimed at treatment de-escalation in appropriately selected patients.
SOURCE:
This study, led by Noémie Villemure-Poliquin, MD, MSc, Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada, was published online in JAMA Otolaryngology-Head & Neck Surgery.
LIMITATIONS:
This study included only patients in Ontario, so findings may not be generalizable to other settings. Reliance on administrative data could have led to misclassification of disease severity and treatment types. Additionally, the analysis did not capture direct out-of-pocket costs.
DISCLOSURES:
This study received support through a grant from the Ontario Ministry of Health and the Ontario Ministry of Long-Term Care. One author reported receiving personal fees from EMD Serono and nonfinancial support from Elekta. Another author reported receiving personal fees from Cancer Care Ontario. No other disclosures were reported.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
10 minutes ago
- Medscape
Fact or Fiction: Noncolorectal Gastrointestinal Cancer
Noncolorectal gastrointestinal (GI) cancers present unique challenges in diagnosis, management, and prognosis. Knowledge of risk factors, presenting features, and contemporary treatment guidelines is essential for timely recognition and effective care. Pancreatic cancer is primarily diagnosed among older adults. Nearly 90% of cases occur in individuals older than 55 years. Besides age, additional risk factors include smoking, diabetes, and obesity. Learn more about pancreatic cancer epidemiology. Due to nonspecific symptoms, most patients with gastric cancer present with advanced disease, contributing to a worldwide 5-year survival rate of approximately 10%. Further, a study of patients with gastric cancer younger than 50 years found that 87% were symptomatic at diagnosis. Learn more about gastric cancer presentation. The incidence of esophageal adenocarcinoma in the US rose dramatically from the 1970s until 2006, then leveled off, and it is also continuing to increase in other countries due to certain lifestyle factors. Surveillance, Epidemiology, and End Results data from 2012-2022 show that incidence rates have remained steady at about 5.0-5.1 per 100,000 in males and 0.6-0.8 per 100,000 in females. Although rising obesity and metabolic syndrome rates probably contributed to prior increases, this does not fully explain the subsequent plateau. Learn more about esophageal cancer epidemiology. Current National Comprehensive Cancer Network (NCCN) guidelines recommend adjuvant chemotherapy after resection of biliary tract cancer; capecitabine is the preferred regimen. American Society of Clinical Oncology guidelines also recommend that patients should undergo adjuvant chemotherapy with capecitabine for 6 months after biliary tract cancer resection. Adjuvant chemotherapy or chemoradiation has been shown to improve survival in patients with biliary tract cancer, with the benefit being particularly notable among those with lymph node involvement. Learn more about biliary tract cancer treatment protocols. Studies have shown that the combination of an immune checkpoint inhibitor (ICI) and a vascular endothelial growth factor (VEGF) inhibitor, rather than a TKI plus cytotoxic chemotherapy, is associated with favorable survival outcomes and has recently become the standard initial treatment for advanced HCC. Although TKI may still be used as systemic therapy, c urrent NCCN guidelines recommend atezolizumab (an ICI) plus bevacizumab (a VEGF inhibitor) as one of the preferred initial systemic therapy regimens for advanced HCC; tremelimumab-actl plus durvalumab (both monoclonal antibody therapies) is another preferred initial option. Learn more about HCC treatments. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.
New York Times
11 minutes ago
- New York Times
Texas A&M mascot Miss Reveille X undergoes surgery to remove eye diagnosed with glaucoma
Texas A&M's official mascot, Miss Reveille X, was diagnosed with glaucoma, according to a statement from Texas A&M president Mark A. Welsh III. Miss Reveille X, a rough collie, experienced 'discomfort' and 'cloudiness' in her right eye. Veterinarians at Texas A&M Veterinary Medical Teaching Hospital recommended that Miss Reveille X undergo surgery. Out of 'an abundance of caution,' her eye was removed. Advertisement 'I'm grateful to report that Miss Rev has come through the surgery successfully, has been discharged and is resting comfortably. Our priority is her health and well-being, and we are blessed to have access to the remarkably talented and caring Texas A&M veterinary team who will continue to monitor Miss Rev on her road to recovery.' Miss Reveille X became the Aggies' mascot on April 30, 2021. She, along with the past mascots, is cared for by the Corps of Cadets Company E-2. On football game days, Miss Reveille X can be seen running out on the field with her handler. The First Lady of Aggieland will take a 'brief hiatus from engagements' as she makes her recovery. 'According to her veterinary team, we can expect Miss Rev to be back to enjoying all her favorite activities — cruising on Rev Force One, attending classes, cheering on the Aggies and keeping our campus squirrels in line — this fall.'
Yahoo
38 minutes ago
- Yahoo
SHA to spend $6.5M on 77 new health-care positions across rural and remote Sask. communities
The Saskatchewan Health Authority (SHA) and the provincial government have announced 77 new and enhanced permanent full-time health-care positions across 30 rural and remote communities in the province. New positions include a wide range of clinical roles such as licensed practical nurses, registered nurses, registered psychiatric nurses, combined lab and x-ray technicians, medical radiation technologists and phlebotomists, SHA said in a news release Wednesday. They will be added to communities including Kindersley, Kipling, La Ronge, Leader, Maple Creek, Melville, Moose Jaw, Nipawin, North Battleford, Outlook, Porcupine Plain, Prince Albert, Redvers, Rosetown, Shaunavon, Shellbrook, Unity, Wadena and Weyburn, the release said. SHA said some of the jobs are new permanent full-time positions, while others are part-time positions being converted to permanent full-time. It said the move will reduce reliance on contract staff and allow for more consistent coverage of emergency departments. In total, $6.2 million will be put toward the positions. The money comes from recent changes to SHA's out-of-scope administrative leadership that reduced 26 senior positions and other corporate, management and support roles, according to the release. Some of these new positions will be eligible for the Saskatchewan Rural and Remote Recruitment Incentive (RRRI), which provides up to $50,000 over three years, the SHA said. The announcement stems from the province's Health Human Resources Action Plan, launched in 2022 to recruit, train, incentivize and retain-health care workers in Saskatchewan, SHA said. SHA said it has already put $4.2 million toward the creation of 27 new and 20 enhanced clinical manager positions across 45 rural and northern communities.
